chore: daily update 2026-07-28
This commit is contained in:
OpenWiki Bot
+66
-1
@@ -1,6 +1,6 @@
|
||||
# Web Search Evidence
|
||||
|
||||
> Connector: `web-search-1` (Tavily). This page records compact, relevant evidence from the 2026-07-26 pull; search results are discovery leads, not vendor-confirmed announcements.
|
||||
> Connector: `web-search-1` (Tavily). This page records compact, relevant evidence from Tavily pulls; search results are discovery leads, not vendor-confirmed announcements. Latest pull: 2026-07-27 18:04 UTC.
|
||||
|
||||
## 2026-07-26 pull
|
||||
|
||||
@@ -109,3 +109,68 @@ Third Tavily pull on the same day, after the 2026-07-27 `~/.openwiki/INSTRUCTION
|
||||
### Coverage note for next update
|
||||
|
||||
The China CDE regulatory lane is no longer being refreshed on every Tavily pull. The existing `/commitments.md` item pins it as `source-backed` with one credible cisema.com source. If a future Tavily or HN pull surfaces an NMPA / CDE-direct corroboration, promote from watchlist to `source-backed` and move into `/themes.md` as a confirmed row.
|
||||
ll
|
||||
|
||||
Fourth Tavily pull on the 2026-07-27 cycle, run as a stand-alone `openwiki personal --update` source ingest. All 10 queries were re-run. Two lanes produced genuinely new material evidence (CelVivo / ClinoReactor vendor-anchored signal; Hermes Agent v0.19 Quicksilver workflow-tooling release). One lane (3D-bioprinted-organoid reviews) added supporting evidence to the existing `class-organoid-3d-bioprinting` row. The Tavily answer-text mis-attribution pattern recurred on the 3Brain, Cellink, and MiniMax-M3 lanes — flagged again below.
|
||||
|
||||
### CelVivo ClinoReactor + TheWell Bioscience xeno-free workflow — source-backed
|
||||
|
||||
This is the **first vendor-anchored CelVivo signal in any Tavily pull**. Prior pulls returned only MO:BOT or generic organoid content. Three TheWell Bioscience pages published in the 2026-07-21 / 2026-07-23 / 2026-07-25 window all reference "CelVivo ClinoReactor™" by name in their product content:
|
||||
|
||||
- **TheWell Bioscience, 2026-07-21:** [Cell Culture Media (Xeno-Free)](https://www.thewellbio.com/product-category/xeno-free-cell-culture-media). Score 0.591. "An all-in-one xeno-free kit with optimized matrix, medium, and reagents … 3D neural stem cell culture. 2026 TheWell Bioscience Inc. CelVivo ClinoReactorTM". Position: ClinoReactor as the vessel in a complete xeno-free workflow.
|
||||
- **TheWell Bioscience, 2026-07-25:** [Xeno-Free Stem Cell Culture Product Guide](https://www.thewellbio.com/xeno-free-stem-cell-culture-guide). Score 0.585. Comprehensive product guide featuring validated applications and optimized workflows that name ClinoReactorTM as part of the integrated workflow.
|
||||
- **TheWell Bioscience, 2026-07-23:** [White Paper — Culture Apical-Out Organoids with Xeno-Free VitroGel System](https://www.thewellbio.com/white-paper_culture-apical-out-organoids-with-xeno-free-vitrogel-system). Score 0.213. "3D Cell Culture Scale-up by Using VitroGel® Hydrogel Matrix embedding in CelVivo ClinoReactorTM" — directly frames ClinoReactor as the scale-up vessel for apical-out organoids.
|
||||
- **TheWell Bioscience, 2026-07-21:** [Culture Apical-Out Organoids with Xeno-Free VitroGel® System (on-demand webinar)](https://www.thewellbio.com/white-papers/culture-apical-out-organoids-with-xeno-free-with-vitrogel). Score 0.179. Companion webinar to the white paper.
|
||||
|
||||
**Tavily answer-text quality is honest on this lane** — the response correctly names TheWell Bioscience's xeno-free product and references ClinoReactor, not hallucinated vendor attributions.
|
||||
|
||||
**Robin relevance:** high. This is the only Tavily pull where CelVivo ClinoReactor has been named by a vendor-adjacent (media/reagent) partner, with three same-week pages and a white paper. Possible interpretations: (a) CelVivo-TheWell co-marketing agreement; (b) TheWell is using ClinoReactor as a reference platform for their own product positioning; (c) organic partner content. Promoted to `/commitments.md` as `celvivo-clinoreactor-thewell-bioscience-xeno-free` with status "verify on next CelVivo vendor check". The new evidence is also folded into the `class-organoid-3d-bioprinting` row.
|
||||
|
||||
### Hermes Agent v0.19 "Quicksilver" Release — source-backed (workflow tooling, low priority)
|
||||
|
||||
The `Hermes Agent MiniMax M3 changelog 2026` query returned a material release note for **Hermes Agent v0.19**, the "Quicksilver" release from Nous Research. Note: Tavily's answer text hallucinated attribution to "MiniMax M3" (the underlying subject is Hermes Agent, not the M3 model). The underlying URLs confirm the release:
|
||||
|
||||
- **Instagram (techkwon reel), no exact date in 2026-07:** [Hermes Agent 0.19 Quicksilver Release notes](https://www.instagram.com/reel/DbB2yomkss8). Score 0.573. Names the v0.19 features: first-token delay 4.3s → 0.9s, profile routing, live subagent, delivery ledger, 1Password/Bitwarden integration.
|
||||
- **Instagram (Nous Research reel), 2026-07-25:** [Hermes Agent v0.19 Quicksilver Release](https://www.instagram.com/reel/DbGaGsoqUUx). Score 0.475. Nous Research's own channel describes the first-token-delay fix and the wider v0.19 feature set.
|
||||
- **Reddit r/hermesagent, 2026-07-22:** [What are your USE CASES for Hermes Agent?](https://www.reddit.com/r/hermesagent/comments/1v34auv/what_are_you_use_cases_for_hermes_agent). Score 0.424. 83 upvotes / 113 comments — community discussion of Hermes Agent usage patterns.
|
||||
- **regolo.ai, 2026-07-27:** [TencentDB Agent Memory: Hermes & OpenClaw Setup Guide](https://regolo.ai/tencentdb-agent-memory-the-complete-guide-to-persistent-memory-for-hermes-and-openclaw-with-zero-data-retention). Score 0.120. Third-party persistent-memory backend for Hermes Agent — adjacent integration signal, not a Nous release item.
|
||||
|
||||
**Robin relevance:** Hermes Agent is Robin's daily-driver stack per `~/.openwiki/INSTRUCTIONS.md`. v0.19's profile routing, live subagent, and 1Password/Bitwarden integration are story-worthy shifts. New theme row `hermes-agent-v0-19-quicksilver` added to `/themes.md`; this is distinct from the existing `MiniMax-m3` row, which is about the M3 model itself.
|
||||
|
||||
**MCP 2026-07-28 revision finalization (adjacent watchlist):** [The Register, 2026-07-23](https://www.theregister.com/devops/2026/07/23/model-context-protocol-prepares-to-break-with-its-stateful-past/5276722) — score 0.059. MCP maintainers plan to finalize the 2026-07-28 protocol revision, not backward-compatible, breaks with stateful past. Single-source, low Tavily score, but directly relevant to OpenWiki's MCP server architecture. Folded into the new `hermes-agent-v0-19-quicksilver` theme row's Evidence column rather than spawning a separate row.
|
||||
|
||||
### 3D bioprinted organoid reviews + Pluristyx hepatocyte manufacturing — folded into `class-organoid-3d-bioprinting`
|
||||
|
||||
Two same-week review papers and one iPSC + aerospace clinical-grade hepatocyte manufacturing press release re-anchor the existing application-domain theme row:
|
||||
|
||||
- **Oxford Academic, 2026-07-27:** [Three-dimensional bioprinted organoids: advances and applications](https://academic.oup.com/rb/article/8722305). Score 0.107. Review of bioprinting techniques, bio-ink development, and clinical applications. Application-domain evidence, not vendor-anchored.
|
||||
- **Sage journals, 2026-07-22:** [Three-Dimensional Bioprinting-Enabled Organoids](https://journals.sagepub.com/doi/10.1177/19373368261469463). Score 0.125. Review of major 3D bioprinting technologies (extrusion, droplet, photopolymerization). Application-domain evidence.
|
||||
- **GlobeNewswire via Manila Times, 2026-07-27:** [Pluristyx Partners With Leading Regenerative Medicine and Aerospace Pioneers to Standardize Clinical-Grade Hepatocyte Manufacturing for Space and Earth Applications](https://www.manilatimes.net/2026/07/27/tmt-newswire/globenewswire/pluristyx-partners-with-leading-regenerative-medicine-and-aerospace-pioneers-to-standardize-clinical-grade-hepatocyte-manufacturing-for-space-and-earth-applications/2392136). Score 0.219. Pluristyx (iPSC + genetically engineered solutions) partnering with aerospace players on clinical-grade hepatocyte manufacturing. Adjacent to ClinoReactor liver-spheroid use cases.
|
||||
|
||||
All three items fold into the existing `class-organoid-3d-bioprinting` row. Last seen refreshed to 2026-07-27; evidence count increased.
|
||||
|
||||
### 3Brain / Cellink / CellShot / installed-base / RAGFlow lanes — no new vendor-anchored evidence; Tavily answer-text mis-attribution recurs
|
||||
|
||||
- **3Brain CorePlate MEA 2026:** the Nature [portable semi-dry EEG device paper](https://www.nature.com/articles/s41598-026-52672-8) reappears at score 0.187. Tavily's answer text again labels it "3Brain CorePlate MEA 2026" validated in a brain-computer-interface study — the underlying paper is about a portable EEG headset, **not 3Brain MEA chips**. Do not promote as 3Brain evidence. Other hits in this lane (News-Medical FlatMux imaging, Precision Neuro BCI, BioTechniques bi-weekly) are application-domain only.
|
||||
- **Cellink BIO X bioprinter 2026:** no direct Cellink result. Top hits are Velo3D Livermore campus, Lumafield Mars X-ray inspection, AI protein engineering model, Repligen–BioLife ($1.5bn cell-therapy acquisition). All unrelated to Cellink BIO X / BIONOVA X / Lumen X. Application-domain only.
|
||||
- **CellShot / CellPick bioprinter 2026:** no Femtobiomed result. Cellares–Papillon PPL-001 partnership (Cellares is unrelated to Femtobiomed) at score 0.201, CCDx whole-cell genomic profiling at 0.164, Nature MO:BOT paper re-mention at 0.074. Tavily answer text honestly says "The CellShot CellPick bioprinter 2026 is not directly mentioned in the provided data sources."
|
||||
- **labs CelVivo ClinoStar installed base 2026:** no direct result. Cepheid GeneXpert third-generation ADLM 2026 (score 0.112) dominates the top slot and is unrelated to CelVivo installed-base. Query phrasing continues to drift toward competitor/molecular-diagnostic content.
|
||||
- **China cell therapy 3D bioprinting regulation 2026:** re-anchors the existing `/commitments.md` `china-cde-cell-gene-therapy-rules-2026` item. Top result: Roots Analysis [Cell Therapy Manufacturing Market Size 2035](https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html) (0.669) re-mentioning Merck's $11.3B Bio-Techne acquisition. Second hit: cisema.com (0.666) — the same China CDE source as the 2026-07-26 18:07 pull.
|
||||
- **OpenWiki connectors Tavily RAGFlow 2026:** Tavily recall still broken. Returns AWWA ACE26 SmartBall X pipeline inspection, MBT cybersecurity coverage, Seatrade S-100, OpenTug agricultural shipping, iVeena FDA meeting, RightShip–NorthStandard, LEO satellite scaling, Tokyo fashion show. None of the 8 results touches Robin's actual stack.
|
||||
- **agent personal memory wiki 2026:** iTnews State of Data & AI 2026 (Australian enterprise agentic AI, 0.403), LangChain4j self-building-agent (0.168), Times of Israel Cursor CVE-2026-48124 (0.121), Ad Age small-agency awards (0.103 / 0.103 / 0.083 / 0.082), MCP 2026-07-28 revision (0.059, see above). Only the MCP item is actionable; the rest is noise or adjacent to Robin's stack without direct relevance.
|
||||
|
||||
### Synthesis result
|
||||
|
||||
- **Two new scope-aligned findings:** (a) CelVivo ClinoReactor + TheWell Bioscience xeno-free workflow (vendor-anchored, first time in any Tavily pull); (b) Hermes Agent v0.19 Quicksilver (workflow tooling, source-backed).
|
||||
- **Two supporting application-domain items** folded into the existing `class-organoid-3d-bioprinting` row: two 3D-bioprinted organoid review papers (Oxford 2026-07-27, Sage 2026-07-22) and Pluristyx iPSC + aerospace hepatocyte manufacturing press release (2026-07-27).
|
||||
- **Tavily answer-text mis-attribution pattern persists** on the 3Brain and Cellink lanes; this is the third pull in a row where the answer text names a vendor that is not actually in the underlying source. Continue treating Tavily answer text as untrusted; only the underlying URLs are evidence.
|
||||
- **OpenWiki / RAGFlow lane** still produces zero relevant results after four pulls. Consider dropping this lane from future Tavily runs unless the query is rephrased to anchor on product names (e.g. "RAGFlow 0.x release notes" instead of "OpenWiki connectors Tavily RAGFlow").
|
||||
|
||||
## Source coverage (cumulative)
|
||||
|
||||
- Pull 1: fetched 2026-07-26T17:39:11Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T17-38-33-286Z/web-search-results.json`
|
||||
- Pull 2: fetched 2026-07-26T18:07:27Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T18-07-14-335Z/web-search-results.json`
|
||||
- Pull 3: fetched 2026-07-26T18:16:21Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T18-16-06-804Z/web-search-results.json`
|
||||
- Pull 4: fetched 2026-07-27T18:04:46Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-27T18-04-01-259Z/web-search-results.json`
|
||||
- Queries: pulls 1, 2, 4 = 10 queries each; pull 3 = 6 queries (vendor-anchored only)
|
||||
- Instance: `web-search-1`
|
||||
|
||||
Reference in New Issue
Block a user